Literature DB >> 24080550

Suppression of TRIF-dependent signaling pathway of toll-like receptors by (E)-1-(2-(2-nitrovinyl)phenyl)pyrrolidine.

Gyo-Jeong Gu1, Sang-Hoon Eom, Chang Won Suh, Kwang Oh Koh, Dae Young Kim, Hyung-Sun Youn.   

Abstract

Toll-like receptors (TLRs) play an important role in the recognition of microbial pathogens and induce innate immune responses. The recognition of microbial components by TLRs triggers the activation of myeloid differential factor 88 (MyD88)- and toll-interleukin-1 receptor domain-containing adapter inducing interferon-β (TRIF)-dependent downstream signaling pathways. Previously, we synthesized (E)-1-(2-(2-nitrovinyl)phenyl)pyrrolidine (NVPP), which contains a nitrovinyl-phenyl and pyrrolidine. To evaluate the therapeutic potential of NVPP, its effect on signal transduction via the TRIF-dependent pathway of TLRs induced by lipopolysaccharide (LPS) or polyinosinic-polycytidylic acid (poly[I:C]) was examined. NVPP inhibited LPS or poly[I:C]-induced activation of nuclear factor-κB (NF-κB) and interferon regulatory factor 3 (IRF3), and the phosphorylation of IRF3, as well as inhibiting the activation of interferon-inducible genes such as interferon inducible protein-10 (IP-10). These results suggest that NVPP can modulate TRIF-dependent signaling pathways of TLRs, potentially resulting in effective therapeutics for chronic inflammatory diseases.
© 2013 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  (E)-1-(2-(2-nitrovinyl)phenyl)pyrrolidine; Interferon regulatory factor 3; Lipopolysaccharide; Polyinosinic-polycytidylic acid; Toll-like receptor

Mesh:

Substances:

Year:  2013        PMID: 24080550     DOI: 10.1016/j.ejphar.2013.09.045

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  1 in total

1.  Dissociation of TRIF bias and adjuvanticity.

Authors:  Katharina Richard; Darren J Perkins; Erin M Harberts; Yang Song; Archana Gopalakrishnan; Kari Ann Shirey; Wendy Lai; Alexandra Vlk; Anup Mahurkar; Shreeram Nallar; Lynn D Hawkins; Robert K Ernst; Stefanie N Vogel
Journal:  Vaccine       Date:  2020-05-07       Impact factor: 3.641

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.